Press releases

Positive preclinical results for the active ingredient in VAL-63-NAFLD on non-alcoholic fatty liver, a risk factor for NASH

December 6th 2017

VALBIOTIS announces positive preclinical results for the active ingredient in VAL-63-NAFLD on non-alcoholic fatty liver (NAFL), a risk factor for NASH.

Read more

Metformin + TOTUM-63 combination: first positive preclinical data for possible use in diabetes real life practice

December 4th 2017

VALBIOTIS announces first positive preclinical data on the combination of TOTUM-63 and metformin, for possible use in diabetes real life practice

Read more

VALEDIA®: launch of “pivotal” REVERSE-IT clinical trial to obtain a health claim

November 8th 2017

VALBIOTIS announces that it has received authorization from the ANSM for the “pivotal” REVERSE-IT international clinical trial evaluating the efficacy of VALEDIA® against risk factors for type 2 diabetes in pre diabetic subjects.

Read more

LIPIDRIVE®: efficacy confirmed in three models, finalization of recruitment for Phase I/II in humans

October 16th 2017

VALBIOTIS announces the efficacy of LIPIDRIVE® is confirmed in three preclinical models and the recruitment for Phase I/II, first study in humans, is being finalized.

Read more